- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors ; volume:8 ; number:1 ; day:4 ; month:4 ; year:2018 ; pages:1-6 ; date:12.2018
EJNMMI Research ; 8, Heft 1 (4.4.2018), 1-6, 12.2018
- Urheber
-
Ardeshirpour, Yasaman
- Beteiligte Personen und Organisationen
-
Sackett, Dan L.
Knutson, Jay R.
Gandjbakhche, Amir H.
SpringerLink (Online service)
- DOI
-
10.1186/s13550-018-0384-6
- URN
-
urn:nbn:de:101:1-2018061016172944943196
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ardeshirpour, Yasaman
- Sackett, Dan L.
- Knutson, Jay R.
- Gandjbakhche, Amir H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry